How many years will it take to take Datopotamab after surgery?

Datopotamab (Datopotamab) is not an oral drug but is administered by intravenous infusion. Its treatment cycle is different from the logic of traditional postoperative oral maintenance drugs and is closer to the long-term continuous treatment model of modern ADC drugs. According to overseas public information, the drug is usually treated with an intravenous infusion regimen every 3 weeks, with a cycle of 21 days, and continues to be used until the disease progresses or the patient cannot tolerate the related adverse reactions. This method of administration emphasizes the continuity of treatment rather than the fixed number of years of treatment, so the traditional maintenance treatment concept of "how many years to take" does not apply.

When using dabrotuzumab postoperatively or after local therapy, the clinical focus is on patient tolerance and tumor (breast cancer, non-small cell lung cancer)control. Since the drug targets TROP2 and carries a potent topoisomerase inhibitor payload, it achieves anti-tumor effects through precise drug release. Therefore, the treatment cycle often depends on the biological characteristics of the disease and the patient's individual response, rather than setting a fixed time. Some overseas experts pointed out that in cases with unresectable or high risk of recurrence, the continuous administration strategy of ADC can maintain the intensity of tumor suppression and reduce the risk of recurrence of micrometastasis, thus emphasizing the value of long-term continuous treatment in cycles.

From the perspective of treatment practice, patients need to be closely monitored for related toxicities during use, including stomatitis, skin reactions, interstitial lung disease, etc. The occurrence of these adverse events may require temporary interruption of the infusion, dose adjustment, or even discontinuation of the drug in severe cases. Therefore, the actual treatment time often varies due to different patient tolerances, and there is no clear guideline for fixed treatment years overseas.

For the postoperative population, dabrotuzumab is still in the clinical expansion research stage, and most research goals are to evaluate its adjuvant therapeutic value in high-risk groups. Therefore, whether a fixed treatment course will be formed in the future still depends on further data.

Reference materials:https://dailymed.nlm.nih.gov/